Close Menu
Daily Guardian
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
What's On

The $200 Popcorn Popper That Keeps Selling Out

October 1, 2026

Challenged Athletes Foundation Receives Rings of Gold Award from U.S. Olympic & Paralympic Committee

October 1, 2026

CleanChoice Energy Closes Approximately $166M in Project Financing and Tax Equity for Two Solar Projects

October 1, 2026

Fabletics Launches Fabletics Reserve Credit Card, Expanding Value and Loyalty Perks to Its More than 2.7 Million Members

October 1, 2026

First Merchants Bank CEO Mark Hardwick to retire at the end of 2026 and President Mike Stewart to become President and CEO

October 1, 2026
Facebook X (Twitter) Instagram
Finance Pro
Facebook X (Twitter) Instagram
Daily Guardian
Subscribe
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
Daily Guardian
Home » U.S. Pharmaceutical Contract Development & Manufacturing Organization Market Analysis Report, with Growth Forecasts for 2025-2033
Press Release

U.S. Pharmaceutical Contract Development & Manufacturing Organization Market Analysis Report, with Growth Forecasts for 2025-2033

By News RoomOctober 27, 20255 Mins Read
U.S. Pharmaceutical Contract Development & Manufacturing Organization Market Analysis Report, with Growth Forecasts for 2025-2033
Share
Facebook Twitter LinkedIn Pinterest Email

Dublin, Oct. 27, 2025 (GLOBE NEWSWIRE) — The “U.S. Pharmaceutical Contract Development & Manufacturing Organization Market Size, Share & Trends Analysis Report by Type, Product, Services, Workflow, Therapeutic Area, End Use, and Growth Forecasts, 2025-2033” report has been added to ResearchAndMarkets.com’s offering.

The U.S. pharmaceutical contract development and manufacturing organization market size was estimated at USD 38.8 Billion in 2025 and is projected to reach USD 65.3 billion by 2033, growing at a CAGR of 6.74% from 2025 to 2033.

The U.S. pharmaceutical contract development & manufacturing organization (CDMO) is advancing, driven by the growth of biologics, biosimilars, and advanced therapies, rising demand for outsourcing in drug development, and increasing clinical trial activity and pipeline expansion.

The U.S. market is witnessing significant growth in biologics, biosimilars, and advanced cell and gene therapies, fueling demand for specialized CDMO services. Developing and manufacturing these therapies requires advanced capabilities like single-use bioprocessing systems, viral vector production, and personalized medicine expertise, which many pharma companies lack in-house.

CDMOs provide infrastructure, regulatory knowledge, and innovation platforms to accelerate development while meeting FDA standards. With rising approvals of biologics and biosimilars in the U.S., CDMOs are becoming indispensable partners in scaling production, ensuring supply chain resilience, and enabling faster time-to-market for complex, high-value therapeutics.

U.S. Pharmaceutical Contract Development and Manufacturing Organization Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the U.S. pharmaceutical CDMO market report based on type, product, service, workflow, therapeutic area, and end use.

Key Attributes:

Report Attribute Details
No. of Pages 120
Forecast Period 2025 – 2033
Estimated Market Value (USD) in 2025 $38.8 Billion
Forecasted Market Value (USD) by 2033 $65.3 Billion
Compound Annual Growth Rate 6.7%
Regions Covered United States

Key Topics Covered:

Chapter 1. Research Methodology and Scope

Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.3. R&D Spending Analysis
3.4. Industry Ecosystem Analysis
3.5. Technology Landscape
3.6. Clinical Trial Volume Analysis, 2024
3.7. Pricing Analysis
3.8. Tariff and Trade Agreement Impact Analysis
3.9. Value Chain Analysis
3.10. Market Analysis Tools

Chapter 4. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market: Type Estimates & Trend Analysis
4.1. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market, by Type: Segment Dashboard
4.2. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market, by Type: Movement Analysis
4.3. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market Estimates & Forecasts, by Type
4.4. Small Molecule
4.4.1. Small Molecule Market Estimates and Forecasts, 2021-2033 (USD Million)
4.4.2. Branded
4.4.3. Generic
4.5. Large Molecule
4.5.1. Large Molecule Market Estimates and Forecasts, 2021-2033 (USD Million)
4.5.2. Biologics
4.5.3. Biosimilar

Chapter 5. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market: Product Estimates & Trend Analysis
5.1. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market, by Product: Segment Dashboard
5.2. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market, by Product: Movement Analysis
5.3. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market Estimates & Forecasts, by Product
5.4. API
5.4.1. API Market Estimates and Forecasts, 2021-2033 (USD Million)
5.4.2. Traditional Active Pharmaceutical Ingredient (Traditional API)
5.4.3. Highly Potent Active Pharmaceutical Ingredient (HP-API)
5.4.4. Biologics
5.4.5. Others
5.5. Drug Product
5.5.1. Drug Product Market Estimates and Forecasts, 2021-2033 (USD Million)
5.5.2. Oral Solid Dose
5.5.3. Semi-Solid Dose
5.5.4. Liquid Dose
5.5.5. Others

Chapter 6. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market: Service Estimates & Trend Analysis
6.1. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market, by Service: Segment Dashboard
6.2. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market, by Service: Movement Analysis
6.3. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market Estimates & Forecasts, by Service
6.4. Contract Development
6.4.1. Contract Development Market Estimates and Forecasts, 2021-2033 (USD Million)
6.4.2. Pre-formulation & Formulation Development Services
6.4.3. Process Development & Optimization
6.4.4. Analytical Testing & Method Validation
6.4.5. Scale-up & Tech Transfer
6.5. Contract Manufacturing
6.5.1. Contract Manufacturing Market Estimates and Forecasts, 2021-2033 (USD Million)
6.5.2. API Manufacturing
6.5.3. Finished Drug Products Manufacturing
6.6. Packaging and Labelling
6.7. Regulatory Affairs
6.8. Others

Chapter 7. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market: Workflow Estimates & Trend Analysis
7.1. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market, by Workflow: Segment Dashboard
7.2. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market, by Workflow: Movement Analysis
7.3. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market Estimates & Forecasts, by Workflow, 2021-2033 (USD Million)
7.4. Clinical
7.5. Commercial

Chapter 8. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market: Therapeutic Area Estimates & Trend Analysis
8.1. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market, by Therapeutic Area: Segment Dashboard
8.2. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market, by Therapeutic Area: Movement Analysis
8.3. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market Estimates & Forecasts, by Therapeutic Area, 2021-2033 (USD Million)
8.4. Oncology
8.5. Infectious Diseases
8.6. Neurological Disorders
8.7. Cardiovascular Diseases
8.8. Metabolic Disorders
8.9. Autoimmune Diseases
8.10. Respiratory Diseases
8.11. Ophthalmology
8.12. Gastrointestinal Disorders
8.13. Orthopedic Diseases
8.14. Dental Diseases
8.15. Others

Chapter 9. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market: End Use Estimates & Trend Analysis
9.1. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market, by End Use: Segment Dashboard
9.2. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market, by End Use: Movement Analysis
9.3. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market Estimates & Forecasts, by End Use, 2021-2033 (USD Million)
9.4. Small Pharmaceutical Companies
9.5. Medium Pharmaceutical Companies
9.6. Large Pharmaceutical Companies

Chapter 10. Competitive Landscape
10.1. Key Participant Categorization
10.2. Market Share/Assessment Analysis, 2024 (Heat Map Analysis)
10.3. Company Profiles

  • Thermo Fisher Scientific, Inc
  • Lonza
  • Recipharm AB
  • Catalent, Inc
  • WuXi AppTec, Inc
  • Samsung Biologics
  • Piramal Pharma Solutions
  • Siegfried Holding AG
  • Corden Pharma International
  • Cambrex Corporation
  • Vetter Pharma
  • Delpharm
  • Jubilant Pharmova / HollisterStier
  • Eurofins CDMO
  • Almac Pharma Services

For more information about this report visit https://www.researchandmarkets.com/r/5f31xu

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

  • U.S. Pharmaceutical Contract Development & Manufacturing Organization Market

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Keep Reading

The $200 Popcorn Popper That Keeps Selling Out

Challenged Athletes Foundation Receives Rings of Gold Award from U.S. Olympic & Paralympic Committee

CleanChoice Energy Closes Approximately $166M in Project Financing and Tax Equity for Two Solar Projects

Fabletics Launches Fabletics Reserve Credit Card, Expanding Value and Loyalty Perks to Its More than 2.7 Million Members

First Merchants Bank CEO Mark Hardwick to retire at the end of 2026 and President Mike Stewart to become President and CEO

Primech Holdings (Nasdaq: PMEC) Unveils Primech Vision, Integrating a Multi-Robot Facility Fleet and Workforce on One Platform; Live Customer Demonstrations Begin October 2026

Easy Environmental Solutions Ships First Commercial EasyFEN™ System to Kenya

The News Forum Presents Aftershock: The World After October 7, 2023

BloFin returns as TOKEN2049 Singapore title sponsor, opens its “NEXT WHALE ERA” chapter with 3rd anniversary afterparty

Editors Picks

Challenged Athletes Foundation Receives Rings of Gold Award from U.S. Olympic & Paralympic Committee

October 1, 2026

CleanChoice Energy Closes Approximately $166M in Project Financing and Tax Equity for Two Solar Projects

October 1, 2026

Fabletics Launches Fabletics Reserve Credit Card, Expanding Value and Loyalty Perks to Its More than 2.7 Million Members

October 1, 2026

First Merchants Bank CEO Mark Hardwick to retire at the end of 2026 and President Mike Stewart to become President and CEO

October 1, 2026

Latest News

Primech Holdings (Nasdaq: PMEC) Unveils Primech Vision, Integrating a Multi-Robot Facility Fleet and Workforce on One Platform; Live Customer Demonstrations Begin October 2026

October 1, 2026

Police seek answers in crash that killed 2 elders, hurt 2 others on BC First Nation

October 1, 2026

An AI agent tried to hack Canadian government website, researchers say

October 1, 2026
Facebook X (Twitter) Pinterest TikTok Instagram
© 2026 Daily Guardian Canada. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.

Go to mobile version